Evogene Asset Resilience Ratio

Latest as of September 2025: 39.61%

Evogene asset resilience ratio. Evogene (EVGN) has an Asset Resilience Ratio of 39.61% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See EVGN defensive asset coverage days to measure how many days the company can operate on defensive assets alone.

Liquid Assets

ILA10.33 Million

≈ $27.70K USD Cash + Short-term Investments

Total Assets

ILA26.09 Million

≈ $69.94K USD All company assets

Resilience Assessment

Very High

Financial Resilience Level

Asset Resilience Ratio of Evogene (2006–2024)

Asset resilience ratio of Evogene from 2006 to 2024. This chart shows how Evogene's Asset Resilience Ratio has changed over time. Read Evogene total liabilities for a breakdown of total debt and financial obligations.

Liquid Assets Composition Over Time

This chart breaks down Evogene's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see EVGN total asset value.

Current Liquid Assets Breakdown

Component	Amount	% of Total Assets
Cash & Equivalents	ILA0.00	0%
Short-term Investments	ILA10.33 Million	39.61%
Total Liquid Assets	ILA10.33 Million	39.61%

Asset Resilience Insights

Very High Liquidity: Evogene maintains exceptional liquid asset reserves at 39.61% of total assets.
This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
The company has significant short-term investments, indicating active treasury management.

Evogene Industry Peers by Asset Resilience Ratio

Compare Evogene's asset resilience ratio with other companies in the same industry.

Company	Industry	Asset Resilience Ratio
Samsung Biologics Co Ltd KO:207940	Biotechnology	15.21%
Verona Pharma plc F:I9SA	Biotechnology	0.00%
Asymchem Laboratories Tian Jin Co Ltd SHE:002821	Biotechnology	5.07%
Immunovant Inc NASDAQ:IMVT	Biotechnology	98.50%
Shanghai Allist Pharmaceuticals Co. Ltd. A SHG:688578	Biotechnology	21.11%
Tubize-Fin BR:TUB	Biotechnology	2.50%
Shanghai RAAS Blood Products Co Ltd Class A SHE:002252	Biotechnology	2.03%
Amicus Therapeutics Inc NASDAQ:FOLD	Biotechnology	8.37%

Evogene Asset Resilience Ratio by Year (2006–2024)

Evogene asset resilience ratio by year from 2006 to 2024. The table below shows the annual Asset Resilience Ratio data for Evogene.

Year	Asset Resilience Ratio (%)	Liquid Assets	Total Assets	Change
2024-12-31	0.03%	ILA10.00K ≈ $26.81	ILA39.86 Million ≈ $106.87K	-20.11pp
2023-12-31	20.14%	ILA10.29 Million ≈ $27.59K	ILA51.10 Million ≈ $137.00K	+8.78pp
2022-12-31	11.36%	ILA6.38 Million ≈ $17.09K	ILA56.13 Million ≈ $150.47K	-16.87pp
2021-12-31	28.23%	ILA21.54 Million ≈ $57.75K	ILA76.30 Million ≈ $204.57K	+25.45pp
2020-12-31	2.78%	ILA2.00 Million ≈ $5.36K	ILA71.92 Million ≈ $192.80K	-14.21pp
2019-12-31	16.99%	ILA12.13 Million ≈ $32.51K	ILA71.36 Million ≈ $191.32K	-65.90pp
2018-12-31	82.90%	ILA48.66 Million ≈ $130.45K	ILA58.69 Million ≈ $157.36K	-5.14pp
2017-12-31	88.04%	ILA68.32 Million ≈ $183.16K	ILA77.60 Million ≈ $208.05K	-0.39pp
2016-12-31	88.42%	ILA84.88 Million ≈ $227.55K	ILA95.99 Million ≈ $257.34K	+8.13pp
2015-12-31	80.30%	ILA90.41 Million ≈ $242.39K	ILA112.59 Million ≈ $301.86K	-5.99pp
2014-12-31	86.28%	ILA110.09 Million ≈ $295.14K	ILA127.59 Million ≈ $342.05K	+63.38pp
2013-12-31	22.91%	ILA31.45 Million ≈ $84.32K	ILA137.31 Million ≈ $368.13K	-24.69pp
2012-12-31	47.60%	ILA30.87 Million ≈ $82.76K	ILA64.86 Million ≈ $173.87K	-29.48pp
2011-12-31	77.07%	ILA52.32 Million ≈ $140.28K	ILA67.89 Million ≈ $182.01K	+17.06pp
2010-12-31	60.01%	ILA25.73 Million ≈ $68.98K	ILA42.87 Million ≈ $114.94K	+31.97pp
2009-12-31	28.04%	ILA12.02 Million ≈ $32.24K	ILA42.88 Million ≈ $114.96K	-15.80pp
2008-12-31	43.84%	ILA14.88 Million ≈ $39.90K	ILA33.95 Million ≈ $91.01K	+38.48pp
2007-12-31	5.36%	ILA572.00K ≈ $1.53K	ILA10.67 Million ≈ $28.60K	-33.08pp
2006-12-31	38.44%	ILA7.50 Million ≈ $20.12K	ILA19.52 Million ≈ $52.34K	--

pp = percentage points

About Evogene

TA:EVGN Israel Biotechnology

Market Cap

$2.24 Million

ILA836.95 Million ILA

Market Cap Rank

#29882 Global

#433 in Israel

Share Price

ILA96.00

Change (1 day)

-11.28%

52-Week Range

ILA96.00 - ILA409.10

All Time High

ILA33620.00